NRG GI004

Official Title

Testing Combination Chemotherapy with or without an Investigational Drug or the Investigational Drug Alone for Metastatic Colon or Rectal Cancer

Study Purpose

To learn if adding the experimental agent atezolizumab (MPDL3280A) to the usual treatment or giving the experimental agent alone is better than the usual treatment alone for metastatic colon or rectal cancer.

Diagnosis

Eligibility

Prior Therapy: No previous chemotherapy or any other systemic therapy for metastatic colorectal cancer is allowed.

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

Group 1 will get FOLFOX and bevacizumab (usual treatment)

Group 2 will get atezolizumab alone (investigational agent only)

Group 3 will receive FOLFOX and bevacizumab plus atezolizumab (usual treatment + investigational drug)